Page 153 - Haematologica August 2018

End-of-life care for myeloma
20. Fletcher SA, Cronin AM, Zeidan AM, et al. Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database. Cancer. 2016;122(8):1209-1215.
21. Odejide OO, Cronin AM, Earle CC, LaCasce AS, Abel GA. Hospice use among patients with lymphoma: impact of disease aggressiveness and curability. J Natl Cancer Inst. 2016;108:1.
22. Wang R, Zeidan AM, Halene S, et al. Health care use by older adults with acute myeloid leukemia at the end of life. J Clin Oncol. 2017;35(30):3417-3424.
23. Earle CC, Landrum MB, Souza JM, Neville BA, Weeks JC, Ayanian JZ. Aggressiveness of cancer care near the end of life: is it a qual- ity-of-care issue? J Clin Oncol. 2008;26(23):3860-3866.
24. Surveillance, epidemiology, and end results program national cancer institute. 2018 [cited 2018 March 12, 2018]; Available from: https:// healthcaredelivery.cancer.gov/seer- medicare/overview/link ed.html
25. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER- Medicare data: content, research applica- tions, and generalizability to the United States elderly population. Med Care. 2002;40(8 Suppl):IV-3-18.
26. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin
Epidemiol. 1992;45(6):613-619.
27. Wright AA, Hatfield LA, Earle CC, Keating
NL. End-of-life care for older patients with ovarian cancer is intensive despite high rates of hospice use. J Clin Oncol. 2014;32(31):3534-3539.
28. Peppercorn JM, Smith TJ, Helft PR, et al. American Society of Clinical Oncology Statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011;29(6):755-760.
29. Partridge AH, Seah DSE, King T, et al. Developing a service model that integrates palliative care throughout cancer care: the time is now. J Clin Oncol. 2014; 32(29):3330- 3336.
30. NHPCO's Report Facts and Figures : Hospice Care in America. 2015 [cited 2018 March 13, 2018]; Available from: https://www.nhpco.org/sites/default/files/p ublic/Statistics_Research/ProviderGrowth.p df
31. Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. Eur J Haematol. 2009;83(2):139-148.
32. Odejide OO, Cronin AM, Condron NB, et al. Barriers to quality end-of-life care for patients with blood cancers. J Clin Oncol. 2016;34(26):3126-3132.
33. Johnson KS, Payne R, Kuchibhatla MN, Tulsky JA. Are hospice admission practices
associated with hospice enrollment for older African Americans and Whites? J Pain Symptom Manage. 2016;51(4):697-705.
34. Odejide OO, Cronin AM, Earle CC, Tulsky JA, Abel GA. Why are patients with blood cancers more likely to die without hospice? Cancer. 2017;123(17):3377-3384.
35. Tamura MK, Cohen LM. Should there be an expanded role for palliative care in end-stage renal disease? Curr Opin Nephrol Hypertens. 2010;19(6):556-560.
36. Odejide OO, Salas Coronado DY, Watts CD, Wright AA, Abel GA. End-of-life care for blood cancers: a series of focus groups with hematologic oncologists. J Oncol Pract. 2014;10(6):e396-403.
37. Howell DA, Wang H-I, Roman E, et al. Variations in specialist palliative care refer- rals: findings from a population-based patient cohort of acute myeloid leukaemia, diffuse large B-cell lymphoma and myelo- ma. BMJ Support Palliat Care. 2015;5(5):496- 502.
38. Howell DA, Wang HI, Smith AG, Howard MR, Patmore RD, Roman E. Place of death in haematological malignancy: variations by disease sub-type and time from diagnosis to death. BMC Palliat Care. 2013;12(1):42.
39. Tang ST, Wu SC, Hung YN, Chen JS, Huang EW, Liu TW. Determinants of aggressive end-of-life care for Taiwanese cancer dece- dents, 2001 to 2006. J Clin Oncol. 2009;27(27):4613-4618.
haematologica | 2018; 103(8)
1389